BioCentury
ARTICLE | Company News

Ablynx, Merck KGaA deal

October 1, 2012 7:00 AM UTC

Ablynx will receive a €1 million ($1.3 million) milestone payment from Merck under a 2008 deal in which Ablynx and Merck's Merck Serono S.A. unit partnered to co-discover and co-develop Ablynx 's Nanobodies against two undisclosed targets in cancer and immunology. The payment was triggered by advancing ALX-0751 into preclinical testing to treat cancer. Last year, Ablynx received a €1 million ($1.3 million) milestone payment under the deal triggered by advancing ALX-0761 into preclinical testing to treat autoimmune diseases. Ablynx declined to disclose details regarding the programs. Nanobodies are therapeutic proteins based on single-domain antibody fragments (see BioCentury, Sept. 8, 2008 & Dec. 19, 2011). ...